Though Bayer Crop Science has spent more than $12 billion defending glyphosate, the company is optimistic a Supreme Court case could clarify the company's use of labels on the popular herbicide.

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales lost to patent expirations.

Last Friday, the U.S. Supreme Court agreed to hear an appeal filed by Bayer over claims against its Roundup weed killer—news that sent the German company’s stock soaring. There’s good reason for the ...

If you've purchased a Bayer spray meant to treat conditions like athletes' foot or ringworm in the last 10 years, you could ...

Preceon Short-Stature Corn from Bayer allows growers to produce more with less but does so while significantly cutting ...

In Bayer’s new “Life Doesn’t Stop for a Hot Flash” campaign, Gabrielle Union-Wade discusses her personal experiences with ...

By Diana Novak Jones Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and ...

Bayer A.G. stock: contrarian Buy with €35 target. Click for this updated look at BAYZF stock prospects and why I am neutral ...

Bayer says it will put more than $45 million toward building a new research and development facility in Winnipeg.

Eintracht Frankfurt host Bayer Leverkusen in a key mid-season clash as both teams target European qualification. Frankfurt ...

As Northern European growers face plant disease and tightening regulations, Bayer launches a new strawberry to meet those ...